Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

May 2, 2017

Study Completion Date

May 2, 2017

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

Z0063

Pharmaceutical form: chewable tablets Route of administration: oral

DRUG

Gaviscon

Pharmaceutical form: chewable tablets Route of administration: oral

Trial Locations (1)

Investigational site 826001, Merthyr Tydfil